Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors

Leukemia. 2012 Sep;26(9):2142-3. doi: 10.1038/leu.2012.73. Epub 2012 Mar 19.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aftercare
  • Antigens, CD34 / metabolism*
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Fusion Proteins, bcr-abl / antagonists & inhibitors*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Neoplasm, Residual / drug therapy*
  • Neoplasm, Residual / metabolism
  • Neoplastic Stem Cells / metabolism
  • Neoplastic Stem Cells / pathology*
  • Piperazines / therapeutic use*
  • Prospective Studies
  • Pyrimidines / therapeutic use*

Substances

  • Antigens, CD34
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl